Sirnaomics has announced the establishment of a strategic partnership with EDIRNA Inc. ("EDIRNA"), providing an initial funding and an exclusive licensing of Sirnaomics proprietary delivery technologies for advancing EDIRNA's proprietary "Edit-to-Cure TherapeuticsTM" platform, targeting diseases with high unmet clinical need.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.24 HKD | +4.69% | +1.45% | -88.24% |
Jul. 08 | Sirnaomics Finds No Serious Adverse Events During Phase 1 Study for Coagulation Drug | MT |
Jul. 08 | Sirnaomics Anticogulent Agent Successfully Completes 2nd Cohort of Phase I Clinical Study | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-88.24% | 45.12M | |
+18.43% | 122B | |
+19.81% | 112B | |
-23.74% | 19.33B | |
-18.45% | 16.17B | |
-19.97% | 15.6B | |
-49.33% | 14.65B | |
+57.08% | 14.34B | |
+7.95% | 14B | |
+126.04% | 11.29B |
- Stock Market
- Equities
- 2257 Stock
- News Sirnaomics Ltd.
- Sirnaomics Ltd. Establishes Strategic Partnership with Edirna Inc